Michael Barbella, Managing Editor04.26.23
egnite Inc. has forged a partnership with physicians from Morristown Medical Center’s Gagnon Cardiovascular Institute—Philippe Généreux, a Structural Heart Program director, and Linda Gillam, chair of Cardiovascular Medicine.
“We are honored to be partnering with doctors Gillam and Généreux, and working with physicians of this caliber will help us accelerate our platform’s innovation,” egnite CEO/President Joel Portice said.
The partnership aims to elevate the standard of care for patients with cardiovascular (CV) disease, which affects an estimated 126 million U.S. adults and is expected to increase by 30% by 2060.
The partnership will spearhead research initiatives to better understand optimal points of therapeutic intervention for patients with valvular heart disease, using egnite’s flagship digital health platform, CardioCare. This initiative furthers the use of precision medicine algorithms to help physicians design and deliver an individualized patient management plan.
“CardioCare’s AI tools will help us ensure that every patient receives optimal evaluation and management of their heart disease,” Gillam stated. “Its big data approach will also help us identify patients who might be candidates for one of many research trials, thereby potentially giving patients access to otherwise unavailable therapeutic options.”
The partnership will also support the expansion of Généreux’s staging research, which examines the value of cardiac staging relating to the treatment and outcomes of AS & MR using the 12 million de-identified cardiovascular encounters in egnite’s database. “I am thrilled to collaborate with egnite’s team and use their incredible platform to better understand valve disease, build meaningful research, and improve patient management and outcomes,” he said.
egnite is a digital health company developing cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company partners with hospitals and life sciences organizations to transform care delivery for cardiovascular patients. The company is based in Aliso Viejo, Calif.
“We are honored to be partnering with doctors Gillam and Généreux, and working with physicians of this caliber will help us accelerate our platform’s innovation,” egnite CEO/President Joel Portice said.
The partnership aims to elevate the standard of care for patients with cardiovascular (CV) disease, which affects an estimated 126 million U.S. adults and is expected to increase by 30% by 2060.
The partnership will spearhead research initiatives to better understand optimal points of therapeutic intervention for patients with valvular heart disease, using egnite’s flagship digital health platform, CardioCare. This initiative furthers the use of precision medicine algorithms to help physicians design and deliver an individualized patient management plan.
“CardioCare’s AI tools will help us ensure that every patient receives optimal evaluation and management of their heart disease,” Gillam stated. “Its big data approach will also help us identify patients who might be candidates for one of many research trials, thereby potentially giving patients access to otherwise unavailable therapeutic options.”
The partnership will also support the expansion of Généreux’s staging research, which examines the value of cardiac staging relating to the treatment and outcomes of AS & MR using the 12 million de-identified cardiovascular encounters in egnite’s database. “I am thrilled to collaborate with egnite’s team and use their incredible platform to better understand valve disease, build meaningful research, and improve patient management and outcomes,” he said.
egnite is a digital health company developing cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company partners with hospitals and life sciences organizations to transform care delivery for cardiovascular patients. The company is based in Aliso Viejo, Calif.